Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Lucy Scientific Discovery (LSDI) has reiterated its proposal to acquire Pasithea Therapeutics at $0.85 per share, a 142% premium to Pasithea's share price. The offer includes $0.60 in cash and $0.25 in LSDI stock for each share of Pasithea.
June 29, 2023 | 6:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics' stock could see a significant increase due to the premium offered by Lucy Scientific Discovery.
The premium offer by Lucy Scientific Discovery could lead to a significant increase in Pasithea's stock price as it indicates a higher valuation of the company.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Lucy Scientific Discovery's proposal to acquire Pasithea Therapeutics could potentially increase its market share and diversify its portfolio.
Acquisitions often lead to an increase in market share and diversification of portfolio. Given the premium offered, it shows Lucy's confidence in the value Pasithea can bring.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100